Global Tuberculosis Treatment Drugs Market

Tuberculosis Treatment Drugs Comprehensive Study by Type (Active TB, Latent TB), Application (Hospital, Clinic, Durgstore), Drugs (First Line anti-TB Drugs, Second Line anti- TB Drugs) Players and Region - Global Market Outlook to 2030

Tuberculosis Treatment Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Tuberculosis Treatment Drugs
Tuberculosis remains a global public health concern. According to the World Health Organization, in 2017, the annual incidence of Tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection 87,000 cases per year. The TB treatment drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. About one third of the worlds's population is suffering with latent tuberculosis, people infected with mycobacterium infection have a 10% risk to fall ill with tuberculosis, however people with compromised immunity such as HIV, diabetes and tobacco addiction are at a higher risk to get tuberculosis.TB is second to HIV as it is the leading infectious killer of the adults worldwide. Apart from its health consequences, there are many economic impact of the disease which is staggering, making TB a major contributor to poverty.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR5.2%


The market is fragmented by numerous players. R&D, M&A, product launch are the key strategy adopted in the global tuberculosis diagnosis and treatment market. These players are collaborating with each other for the growth and improvement of the Tuberculosis Drugs & Treatment market. For instance, In 2017, Johnson & Johnson entered into a partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to accelerate the discovery of a novel treatment for tuberculosis. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Tuberculosis Treatment Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Johnson & Johnson Inc. (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Eli Lilly (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Novartis International AG (India), Macleods Pharmaceuticals (India), Otsuka Pharmaceutical Co.Ltd. (Japan), AbbVie Inc. (United States) and Takeda Pharmaceutical Company Limited (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Tuberculosis Treatment Drugs market by Type (Active TB and Latent TB), Application (Hospital, Clinic and Durgstore) and Region.



On the basis of geography, the market of Tuberculosis Treatment Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. First Line anti-TB Drugs will boost the Tuberculosis Treatment Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing government and non-government initiatives i.e. DOTS to eradicate tuberculosis and Promising pipeline for the treatment of tuberculosis.

Market Growth Drivers:
High incidence of drug-susceptible (DS) tuberculosis (TB), Increase in multi-drug resistant (MDR) TB cases and Growth in R&D efforts towards Drug Development.

Challenges:
Management of MDR-TB is difficult, much expensive, challenging and quite often leads to failures.

Restraints:
The high-cost factor associated with the treatment of Tuberculosis may hamper the Global Tuberculosis Treatment Drugs market.

Opportunities:
Extensive awareness campaigns and initiatives by various governments to curb the menace is providing an opportunity to the market.

Market Leaders and their expansionary development strategies
In August 2023, The Bill & Melinda Gates Foundation joins forces with PATH to develop and deliver affordable, shorter MDR-TB treatment regimens to patients worldwide.
In October 2023, Gilead Sciences announces positive Phase 3 trial results for its new drug lenacapavir, potentially shortening MDR-TB treatment regimens.


Key Target Audience
Tuberculosis Treatment Drugs Manufacturers, Traders/Retailers/Suppliers/Distributors, Government & Regulatory Agencies, Potential Investors, Health Care Facilities and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Active TB
  • Latent TB
By Application
  • Hospital
  • Clinic
  • Durgstore
By Drugs
  • First Line anti-TB Drugs
  • Second Line anti- TB Drugs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High incidence of drug-susceptible (DS) tuberculosis (TB)
      • 3.2.2. Increase in multi-drug resistant (MDR) TB cases
      • 3.2.3. Growth in R&D efforts towards Drug Development.
    • 3.3. Market Challenges
      • 3.3.1. Management of MDR-TB is difficult, much expensive, challenging and quite often leads to failures.
    • 3.4. Market Trends
      • 3.4.1. Increasing government and non-government initiatives i.e. DOTS to eradicate tuberculosis
      • 3.4.2. Promising pipeline for the treatment of tuberculosis.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculosis Treatment Drugs, by Type, Application, Drugs and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Tuberculosis Treatment Drugs (Value)
      • 5.2.1. Global Tuberculosis Treatment Drugs by: Type (Value)
        • 5.2.1.1. Active TB
        • 5.2.1.2. Latent TB
      • 5.2.2. Global Tuberculosis Treatment Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Durgstore
      • 5.2.3. Global Tuberculosis Treatment Drugs by: Drugs (Value)
        • 5.2.3.1. First Line anti-TB Drugs
        • 5.2.3.2. Second Line anti- TB Drugs
      • 5.2.4. Global Tuberculosis Treatment Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Tuberculosis Treatment Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Labatec Pharma SA (Jordan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sandoz S.A (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tuberculosis Treatment Drugs Sale, by Type, Application, Drugs and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Tuberculosis Treatment Drugs (Value)
      • 7.2.1. Global Tuberculosis Treatment Drugs by: Type (Value)
        • 7.2.1.1. Active TB
        • 7.2.1.2. Latent TB
      • 7.2.2. Global Tuberculosis Treatment Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Durgstore
      • 7.2.3. Global Tuberculosis Treatment Drugs by: Drugs (Value)
        • 7.2.3.1. First Line anti-TB Drugs
        • 7.2.3.2. Second Line anti- TB Drugs
      • 7.2.4. Global Tuberculosis Treatment Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tuberculosis Treatment Drugs: by Type(USD Million)
  • Table 2. Tuberculosis Treatment Drugs Active TB , by Region USD Million (2018-2023)
  • Table 3. Tuberculosis Treatment Drugs Latent TB , by Region USD Million (2018-2023)
  • Table 4. Tuberculosis Treatment Drugs: by Application(USD Million)
  • Table 5. Tuberculosis Treatment Drugs Hospital , by Region USD Million (2018-2023)
  • Table 6. Tuberculosis Treatment Drugs Clinic , by Region USD Million (2018-2023)
  • Table 7. Tuberculosis Treatment Drugs Durgstore , by Region USD Million (2018-2023)
  • Table 8. Tuberculosis Treatment Drugs: by Drugs(USD Million)
  • Table 9. Tuberculosis Treatment Drugs First Line anti-TB Drugs , by Region USD Million (2018-2023)
  • Table 10. Tuberculosis Treatment Drugs Second Line anti- TB Drugs , by Region USD Million (2018-2023)
  • Table 11. South America Tuberculosis Treatment Drugs, by Country USD Million (2018-2023)
  • Table 12. South America Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 13. South America Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 14. South America Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 15. Brazil Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 16. Brazil Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 17. Brazil Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 18. Argentina Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 19. Argentina Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 20. Argentina Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 21. Rest of South America Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 24. Asia Pacific Tuberculosis Treatment Drugs, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 28. China Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 29. China Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 30. China Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 31. Japan Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 32. Japan Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 33. Japan Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 34. India Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 35. India Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 36. India Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 37. South Korea Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 38. South Korea Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 39. South Korea Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 40. Taiwan Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 41. Taiwan Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 42. Taiwan Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 43. Australia Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 44. Australia Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 45. Australia Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 49. Europe Tuberculosis Treatment Drugs, by Country USD Million (2018-2023)
  • Table 50. Europe Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 51. Europe Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 52. Europe Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 53. Germany Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 54. Germany Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 55. Germany Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 56. France Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 57. France Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 58. France Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 59. Italy Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 60. Italy Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 61. Italy Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 62. United Kingdom Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 65. Netherlands Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 66. Netherlands Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 67. Netherlands Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 68. Rest of Europe Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 71. MEA Tuberculosis Treatment Drugs, by Country USD Million (2018-2023)
  • Table 72. MEA Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 73. MEA Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 74. MEA Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 75. Middle East Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 76. Middle East Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 77. Middle East Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 78. Africa Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 79. Africa Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 80. Africa Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 81. North America Tuberculosis Treatment Drugs, by Country USD Million (2018-2023)
  • Table 82. North America Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 83. North America Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 84. North America Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 85. United States Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 86. United States Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 87. United States Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 88. Canada Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 89. Canada Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 90. Canada Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 91. Mexico Tuberculosis Treatment Drugs, by Type USD Million (2018-2023)
  • Table 92. Mexico Tuberculosis Treatment Drugs, by Application USD Million (2018-2023)
  • Table 93. Mexico Tuberculosis Treatment Drugs, by Drugs USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Tuberculosis Treatment Drugs: by Type(USD Million)
  • Table 105. Tuberculosis Treatment Drugs Active TB , by Region USD Million (2025-2030)
  • Table 106. Tuberculosis Treatment Drugs Latent TB , by Region USD Million (2025-2030)
  • Table 107. Tuberculosis Treatment Drugs: by Application(USD Million)
  • Table 108. Tuberculosis Treatment Drugs Hospital , by Region USD Million (2025-2030)
  • Table 109. Tuberculosis Treatment Drugs Clinic , by Region USD Million (2025-2030)
  • Table 110. Tuberculosis Treatment Drugs Durgstore , by Region USD Million (2025-2030)
  • Table 111. Tuberculosis Treatment Drugs: by Drugs(USD Million)
  • Table 112. Tuberculosis Treatment Drugs First Line anti-TB Drugs , by Region USD Million (2025-2030)
  • Table 113. Tuberculosis Treatment Drugs Second Line anti- TB Drugs , by Region USD Million (2025-2030)
  • Table 114. South America Tuberculosis Treatment Drugs, by Country USD Million (2025-2030)
  • Table 115. South America Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 116. South America Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 117. South America Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 118. Brazil Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 119. Brazil Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 120. Brazil Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 121. Argentina Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 122. Argentina Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 123. Argentina Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 124. Rest of South America Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 125. Rest of South America Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 126. Rest of South America Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 127. Asia Pacific Tuberculosis Treatment Drugs, by Country USD Million (2025-2030)
  • Table 128. Asia Pacific Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 129. Asia Pacific Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 130. Asia Pacific Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 131. China Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 132. China Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 133. China Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 134. Japan Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 135. Japan Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 136. Japan Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 137. India Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 138. India Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 139. India Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 140. South Korea Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 141. South Korea Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 142. South Korea Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 143. Taiwan Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 144. Taiwan Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 145. Taiwan Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 146. Australia Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 147. Australia Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 148. Australia Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 152. Europe Tuberculosis Treatment Drugs, by Country USD Million (2025-2030)
  • Table 153. Europe Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 154. Europe Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 155. Europe Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 156. Germany Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 157. Germany Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 158. Germany Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 159. France Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 160. France Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 161. France Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 162. Italy Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 163. Italy Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 164. Italy Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 165. United Kingdom Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 166. United Kingdom Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 167. United Kingdom Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 168. Netherlands Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 169. Netherlands Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 170. Netherlands Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 171. Rest of Europe Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 172. Rest of Europe Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 173. Rest of Europe Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 174. MEA Tuberculosis Treatment Drugs, by Country USD Million (2025-2030)
  • Table 175. MEA Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 176. MEA Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 177. MEA Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 178. Middle East Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 179. Middle East Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 180. Middle East Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 181. Africa Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 182. Africa Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 183. Africa Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 184. North America Tuberculosis Treatment Drugs, by Country USD Million (2025-2030)
  • Table 185. North America Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 186. North America Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 187. North America Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 188. United States Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 189. United States Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 190. United States Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 191. Canada Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 192. Canada Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 193. Canada Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 194. Mexico Tuberculosis Treatment Drugs, by Type USD Million (2025-2030)
  • Table 195. Mexico Tuberculosis Treatment Drugs, by Application USD Million (2025-2030)
  • Table 196. Mexico Tuberculosis Treatment Drugs, by Drugs USD Million (2025-2030)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tuberculosis Treatment Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Tuberculosis Treatment Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Tuberculosis Treatment Drugs: by Drugs USD Million (2018-2023)
  • Figure 7. South America Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 8. Asia Pacific Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 9. Europe Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 10. MEA Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 11. North America Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 12. Global Tuberculosis Treatment Drugs share by Players 2023 (%)
  • Figure 13. Global Tuberculosis Treatment Drugs share by Players (Top 3) 2023(%)
  • Figure 14. Global Tuberculosis Treatment Drugs share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson Inc. (United States) Revenue: by Geography 2023
  • Figure 18. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 19. Lupin Limited (India) Revenue: by Geography 2023
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 24. Labatec Pharma SA (Jordan) Revenue, Net Income and Gross profit
  • Figure 25. Labatec Pharma SA (Jordan) Revenue: by Geography 2023
  • Figure 26. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan N.V (United States) Revenue: by Geography 2023
  • Figure 28. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi S.A (France) Revenue: by Geography 2023
  • Figure 30. Sandoz S.A (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Sandoz S.A (Germany) Revenue: by Geography 2023
  • Figure 32. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 34. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 36. Global Tuberculosis Treatment Drugs: by Type USD Million (2025-2030)
  • Figure 37. Global Tuberculosis Treatment Drugs: by Application USD Million (2025-2030)
  • Figure 38. Global Tuberculosis Treatment Drugs: by Drugs USD Million (2025-2030)
  • Figure 39. South America Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 40. Asia Pacific Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 41. Europe Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 42. MEA Tuberculosis Treatment Drugs Share (%), by Country
  • Figure 43. North America Tuberculosis Treatment Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson Inc. (United States)
  • Lupin Limited (India)
  • Pfizer Inc. (United States)
  • Eli Lilly and Company (United States)
  • Labatec Pharma SA (Jordan)
  • Mylan N.V (United States)
  • Sanofi S.A (France)
  • Sandoz S.A (Germany)
  • Eli Lilly (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Novartis International AG (India) , Macleods Pharmaceuticals (India) , Otsuka Pharmaceutical Co.Ltd. (Japan) , AbbVie Inc. (United States) , Takeda Pharmaceutical Company Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 229 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tuberculosis Treatment Drugs Market Quantitative research analysis
Global Tuberculosis Treatment Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Johnson & Johnson Inc. (United States), Lupin Limited (India), Pfizer Inc. (United States), Eli Lilly and Company (United States), Labatec Pharma SA (Jordan), Mylan N.V (United States), Sanofi S.A (France), Sandoz S.A (Germany), Eli Lilly (United States) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing government and non-government initiatives i.e. DOTS to eradicate tuberculosis " is seen as one of major influencing trends for Tuberculosis Treatment Drugs Market during projected period 2023-2030.
The Tuberculosis Treatment Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Tuberculosis Treatment Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Acute Disease Comprehensive Study by Type (Acute minor illness (self-limiting), Acute major illness (self-limiting or requiring treatment), Acute presentation of existing major illness (acute exacerb...
$ 3650
Bone Growth Stimulator Comprehensive Study by Application (Spinal Fusion, Delay Union & Non-union Bone Fracture, Oral-maxillofacial, Other Applications), Stimulators (Internal Bone Growth Stimulators...
$ 3750
Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdi...
$ 3800
Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement T...
$ 3750
Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global M...
$ 3500
Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation The...
$ 3650